CAPROCK Group Inc. lowered its stake in shares of ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) by 0.7% during the second quarter, Holdings Channel reports. The fund owned 4,560 shares of the specialty pharmaceutical company’s stock after selling 31 shares during the period. CAPROCK Group Inc.’s holdings in ANI Pharmaceuticals were worth $213,000 at the end of the most recent reporting period.

Other hedge funds also recently made changes to their positions in the company. Great West Life Assurance Co. Can boosted its stake in shares of ANI Pharmaceuticals by 8.6% in the second quarter. Great West Life Assurance Co. Can now owns 12,614 shares of the specialty pharmaceutical company’s stock worth $590,000 after buying an additional 1,000 shares during the last quarter. Municipal Employees Retirement System of Michigan boosted its stake in shares of ANI Pharmaceuticals by 132.0% in the second quarter. Municipal Employees Retirement System of Michigan now owns 4,200 shares of the specialty pharmaceutical company’s stock worth $197,000 after buying an additional 2,390 shares during the last quarter. Thomson Horstmann & Bryant Inc. boosted its stake in shares of ANI Pharmaceuticals by 51.4% in the second quarter. Thomson Horstmann & Bryant Inc. now owns 13,505 shares of the specialty pharmaceutical company’s stock worth $632,000 after buying an additional 4,582 shares during the last quarter. Skandinaviska Enskilda Banken AB publ bought a new stake in shares of ANI Pharmaceuticals during the first quarter worth $238,000. Finally, Ranger Investment Management L.P. bought a new stake in shares of ANI Pharmaceuticals during the first quarter worth $769,000. Institutional investors and hedge funds own 56.03% of the company’s stock.

Shares of ANI Pharmaceuticals, Inc. (ANIP) opened at 44.02 on Tuesday. ANI Pharmaceuticals, Inc. has a 12 month low of $42.56 and a 12 month high of $70.92. The stock’s 50 day moving average price is $47.32 and its 200-day moving average price is $50.93. The firm has a market capitalization of $512.26 million, a PE ratio of 137.56 and a beta of 3.08.

ANI Pharmaceuticals (NASDAQ:ANIP) last announced its quarterly earnings results on Thursday, August 3rd. The specialty pharmaceutical company reported $0.98 EPS for the quarter, topping analysts’ consensus estimates of $0.79 by $0.19. The firm had revenue of $44.80 million during the quarter, compared to analysts’ expectations of $43.20 million. ANI Pharmaceuticals had a net margin of 3.35% and a return on equity of 22.70%. The company’s revenue for the quarter was up 43.0% compared to the same quarter last year. During the same quarter last year, the company earned $1.11 earnings per share. On average, equities analysts anticipate that ANI Pharmaceuticals, Inc. will post $3.82 earnings per share for the current fiscal year.

ILLEGAL ACTIVITY WARNING: “CAPROCK Group Inc. Lowers Position in ANI Pharmaceuticals, Inc. (ANIP)” was originally posted by Daily Political and is the sole property of of Daily Political. If you are reading this piece of content on another website, it was illegally stolen and reposted in violation of US and international trademark & copyright legislation. The original version of this piece of content can be read at https://www.dailypolitical.com/2017/08/08/caprock-group-inc-lowers-position-in-ani-pharmaceuticals-inc-anip.html.

A number of analysts have recently weighed in on ANIP shares. Canaccord Genuity started coverage on ANI Pharmaceuticals in a research report on Monday, July 31st. They set a “buy” rating and a $60.00 price target on the stock. Guggenheim reiterated a “buy” rating and set a $80.00 price target on shares of ANI Pharmaceuticals in a research report on Tuesday, July 4th. Roth Capital set a $56.00 price target on ANI Pharmaceuticals and gave the stock a “hold” rating in a research report on Saturday, May 6th. Zacks Investment Research upgraded ANI Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Wednesday, May 3rd. Finally, ValuEngine cut ANI Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Friday, June 2nd. One analyst has rated the stock with a sell rating, three have given a hold rating and two have issued a buy rating to the company. The stock presently has an average rating of “Hold” and a consensus price target of $65.33.

About ANI Pharmaceuticals

ANI Pharmaceuticals, Inc is an integrated specialty pharmaceutical company. The Company is engaged in developing, manufacturing and marketing branded and generic prescription pharmaceuticals. The Company focuses on areas, including controlled substances, anti-cancer (oncolytics), hormones and steroids, and complex formulations.

Want to see what other hedge funds are holding ANIP? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for ANI Pharmaceuticals, Inc. (NASDAQ:ANIP).

Institutional Ownership by Quarter for ANI Pharmaceuticals (NASDAQ:ANIP)

Receive News & Ratings for ANI Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ANI Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.